Stocks Health care PRLD
NASDAQ · Health carePrelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc brought in $22.4M of revenue over the twelve months to June 30, 2026. It posted a net loss of $60.5M. In fiscal 2025 capital spending exceeded operating cash flow by $56.4M. At June 30, 2026 it held $26.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Prelude Therapeutics Inc
- Net worth
- Prelude Therapeutics Inc has a market value (market cap) of $291.3M at the latest share price, and shareholders' equity of $133.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $12.1M (+73.4% year on year), with a net loss of $99.5M. Over the 12 months to June 30, 2026: revenue $22.4M, net loss $60.5M.
- Cash flow
- In fiscal 2025 operations used $56.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Prelude Therapeutics Inc's next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Prelude Therapeutics Inc does
Prelude Therapeutics Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PRLD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $12.1M | -$99.5M | -$1.29 | -$56.4M |
| 2024 | $7M | -$127.2M | -$1.68 | -$103.7M |
| 2023 | n/a | -$121.8M | -$2.02 | -$110.6M |
| 2022 | n/a | -$115.4M | -$2.44 | -$86.7M |
| 2021 | n/a | -$111.7M | -$2.43 | -$85.9M |
| 2020 | n/a | -$56.9M | -$4.56 | -$46.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PRLD ranks in Health care
Latest SEC filings
What Prelude Therapeutics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 10, 2026
- August 11, 2026
- August 11, 2026
- July 8, 2026Passive stake (5% or more) SCHEDULE 13G
- June 10, 2026
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026Revenue was $4.6M; diluted EPS -$0.13 versus -$0.42.
- May 12, 2026
- April 29, 2026
- April 29, 2026Additional proxy material DEFA14A
- April 29, 2026Proxy statement DEF 14A
Insider trades
What the people running Prelude Therapeutics Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| April 27, 2026 | Ra Capital Management, L.P.10% owner | Other changeindirect | 1,407,000 | - |
| April 21, 2026 | Orbimed Advisors LLCDirector, 10% owner | Boughtindirect | 1,689,189 | $7.5M |
| April 21, 2026 | Orbimed Advisors LLCDirector, 10% owner | Boughtindirect | 1,126,126 | $5M |
| April 21, 2026 | Bonita David PDirector, 10% owner | Boughtindirect | 1,689,189 | $7.5M |
| April 21, 2026 | Bonita David PDirector, 10% owner | Boughtindirect | 1,126,126 | $5M |
Who owns PRLD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Orbimed Advisors LLC13D, may seek influence with 3 related filers | 16% | April 23, 2026 |
| Baker Bros. Advisors LP13D, may seek influence with 3 related filers | 15.5% | April 22, 2026 |
| Vaddi Krishna13G, passive | 13.15% | February 13, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | April 28, 2026 |
| Soleus Capital Management, L.P.13G, passive with 8 related filers | 5.2% | July 8, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 75 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Orbimed Advisors LLC | 13,724,571 | +2,815,315 |
| Baker Bros. Advisors LP | 10,123,824 | 0 |
| RA Capital Management, L.P. | 6,475,882 | new |
| Soleus Capital Management, L.P. | 3,378,378 | new |
| Kynam Capital Management, LP | 2,415,087 | +822,536 |
| Vanguard Capital Management LLC | 2,009,445 | +779,039 |
| BlackRock, Inc. | 1,797,501 | +1,475,615 |
| Sphera Funds Management Ltd. | 1,019,832 | +461,493 |
| Two Sigma Investments, LP | 993,369 | +69,743 |
| ADAR1 Capital Management, LLC | 900,900 | +748,075 |
| Millennium Management LLC | 844,993 | +462,256 |
| Geode Capital Management, LLC | 841,862 | +539,404 |
| Adage Capital Partners GP, L.L.C. | 766,095 | new |
| Morgan Stanley | 503,860 | +181,699 |
| State Street Corp | 428,787 | +290,556 |
| UBS Group AG | 318,797 | +254,292 |
| Vanguard Fiduciary Trust Co | 284,886 | +127,506 |
| Renaissance Technologies LLC | 281,200 | +6,000 |
| Northern Trust Corp | 240,599 | +190,479 |
| Vanguard Portfolio Management LLC | 193,920 | new |
Insiders
3 insiders reported holding 8,728,134 shares in total, about $31.9M at the last price.
| Holder | Shares |
|---|---|
| Ra Capital Management, L.P.10% owner | 6,475,8826,475,882 held indirectly |
| Orbimed Advisors LLCDirector, 10% owner | 1,126,1261,126,126 held indirectly |
| Bonita David PDirector, 10% owner | 1,126,1261,126,126 held indirectly |
Questions about PRLD
What does Prelude Therapeutics Inc do?
Prelude Therapeutics Inc is a company in the Health care sector, listed on NASDAQ as PRLD. Its shares trade on NASDAQ under the ticker PRLD.
What is Prelude Therapeutics Inc's net worth?
Prelude Therapeutics Inc has a market value (market cap) of $291.3M at the latest share price, and shareholders' equity of $133.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Prelude Therapeutics Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $60.5M on revenue of $22.4M.
How much revenue does Prelude Therapeutics Inc make?
Over the twelve months to June 30, 2026 Prelude Therapeutics Inc reported revenue of $22.4M.
When did Prelude Therapeutics Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 10, 2026.
When is Prelude Therapeutics Inc's next earnings report?
Prelude Therapeutics Inc's next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PRLD with
Follow PRLD
Get an email when Prelude Therapeutics Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Prelude Therapeutics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.